Avacopan for ANCA vasculitis (GPA or MPA)
Treatments studied
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This study tests an oral medication called avacopan for people with active ANCA-associated vasculitis (GPA or MPA). It’s for those who need strong treatment to control their disease and aims to see if avacopan works as well as standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a new or returning case of GPA (Wegener's) or microscopic polyangiitis that needs strong treatment like cyclophosphamide or rituximab.
- You need to be 18 or older and have a positive ANCA antibody test (past or present).
- Your vasculitis must be active enough—like causing serious kidney problems, lung bleeding, or at least three other symptoms.
- Your kidney function (eGFR) must be 15 or higher.
- You cannot have recently had certain other treatments, severe infections, heart problems, or certain cancers in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR T-cell therapy (CC-97540) for people with active ANCA vasculitis (GPA or MPA) that has not responded to or has returned after standard treatments. The goal is to see if this personalized cell therapy can calm the immune system and reduce disease activity.
This study looks at how well the drug avacopan works for people with a rare blood vessel disease called ANCA-associated vasculitis. It aims to help patients who are starting this treatment by tracking real-world results.
This trial tests if adding avacopan to standard treatments (rituximab or cyclophosphamide plus steroids) helps patients with severe kidney inflammation from a type of vasculitis. It may offer a new option for preserving kidney function.
This trial tests a new way to deliver avacopan—a drug that reduces inflammation in rare blood vessel diseases (ANCA-associated vasculitis)—through a feeding tube instead of by mouth. The study measures how much of the drug reaches your bloodstream and checks if it's safe for patients with very severe disease who are on a breathing machine.
This study compares a new drug (avacopan) with lower doses of steroids to standard steroid treatment for people newly diagnosed with ANCA-associated vasculitis. The goal is to see if avacopan can control your disease with fewer steroid side effects.
This study looks at the long-term safety and effectiveness of avacopan in people with certain types of vasculitis (GPA or MPA). It may help doctors understand how well the medicine works over time.
Hear when a new Antineutrophil Cytoplasmic Antibody-associated Vasculitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.